ELYM vs. XBIT, CGEN, SELB, MRNS, CUE, GYRE, IMNM, SPRY, ZNTL, and CVAC
Should you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include XBiotech (XBIT), Compugen (CGEN), Selecta Biosciences (SELB), Marinus Pharmaceuticals (MRNS), Cue Biopharma (CUE), Gyre Therapeutics (GYRE), Immunome (IMNM), ARS Pharmaceuticals (SPRY), Zentalis Pharmaceuticals (ZNTL), and CureVac (CVAC). These companies are all part of the "medical" sector.
XBiotech (NASDAQ:XBIT) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, community ranking, media sentiment and profitability.
XBiotech's return on equity of -13.32% beat Eliem Therapeutics' return on equity.
XBiotech has higher revenue and earnings than Eliem Therapeutics.
XBiotech has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.36, suggesting that its stock price is 136% less volatile than the S&P 500.
XBiotech received 308 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 69.98% of users gave XBiotech an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote.
In the previous week, Eliem Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 4 mentions for Eliem Therapeutics and 3 mentions for XBiotech. XBiotech's average media sentiment score of 1.19 beat Eliem Therapeutics' score of 0.63 indicating that Eliem Therapeutics is being referred to more favorably in the news media.
55.7% of XBiotech shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 33.1% of XBiotech shares are owned by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
XBiotech beats Eliem Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Eliem Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eliem Therapeutics Competitors List
Related Companies and Tools
